NCT06698822 2025-12-15
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
M.D. Anderson Cancer Center
Phase 2 Recruiting
M.D. Anderson Cancer Center
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's